Zaidoon A. Musa; Ban J. Qasim; A.Wahab A.K. Al Shaikhly
Abstract
Background and Objective:Determination of HER2 gene is crucial in breast carcinoma management and prognosis, as HER2 alterations are linked to a shorter disease-free period, overall survival and resistance to tamoxifen anti-estrogen therapy and other chemotherapy regimens, regardless of the nodal or ...
Read More
Background and Objective:Determination of HER2 gene is crucial in breast carcinoma management and prognosis, as HER2 alterations are linked to a shorter disease-free period, overall survival and resistance to tamoxifen anti-estrogen therapy and other chemotherapy regimens, regardless of the nodal or hormone receptor status. This study aimed to estimate HER2 gene status of infiltrative mammary cancer cases with immunohistochemically equivocal (2+) score using Silver DNA in Situ Hybridization(SISH) technique and to investigate its association with clinicopathological variables. Methods: The study included 52 formalin-fixed paraffin embedded tissue blocks from female patients with invasive breast carcinoma with score of 2+ (equivocal) HER2 immunohistochemistry. All cases were studied by silver DNA in situ hybridization technique (SISH) for the determination of the amplified HER2 DNA. Results: TheSISH technique showed that HER2 gene was not amplified in 33 cases out of 52 (63.5%); while the rest of 19 cases (36.5%) revealed amplified gene status.According to age, HER2 gene status reported non-significant difference in the age groups between cases with amplified and non-amplified gene status (P=0.173). There was a significant negative association between positive Estrogen (ER) and Progesterone (PR) status and HER2 gene amplification (P= 0.002 and 0.017, respectively). Conclusion: More than half of breast carcinoma cases with equivocal HER2 immunoreactivity showed non-amplified gene status; this needs to be considered by oncologists in their management planning of breast cancer. Amplified HER2 gene is significantly associated with negative ER and PR status that affects patients’ management protocols and future outcome of the disease.
Mohammed Chaloob; Alaa G. Hussein; Ban Qasim
Volume 11, Issue 4 , October 2016, , Pages 377-390
Abstract
Background: This research was accomplished to evaluate the IHC expression of p16 (ink4a) and CK17 in low grade cervical intraepithelial lesions (LSIL), high grade cervical intraepithelial lesions (HSIL) and invasive cervical carcinomas and to assess their correlation to HPV (16E6+18E6). Methods: The ...
Read More
Background: This research was accomplished to evaluate the IHC expression of p16 (ink4a) and CK17 in low grade cervical intraepithelial lesions (LSIL), high grade cervical intraepithelial lesions (HSIL) and invasive cervical carcinomas and to assess their correlation to HPV (16E6+18E6). Methods: The study included (127) formalin-fixed paraffin-embedded cervical biopsies; of which 22 cases were chronic cervicitis, 24 cases were LSIL, 28 cases were HSIL and 53 cases were invasive cervical carcinomas. Sections were immunohistochemically stained for p16 (ink4a), CK17 and HPV (16E6+18E6). Results: The study established a highly significant increase in IHC of expression of p16 (ink4a), CK17 and HPV (16E6+18E6) from LSIL through HSIL to invasive carcinomas (P-value˂0.001). There was non-significant association between IHC expression of all makers with age of patients; types, grade and stage of cervical carcinomas (P-value˃0.05). HPV (16E6+18E6) revealed a significantly positive correlation with p16 (ink4a) (P-value˂0.05) and a non- significant correlation with CK17 (P-value˃0.05); in LSIL, HSIL and invasive carcinoma cases. Conclusion: p16 (ink4a) expression directly reflects infection with high risk HPV in cervical lesions and can add a significant diagnostic accuracy in the evaluation of CIN. CK 17 is a good marker of malignant transformation, with increasing in its expression according to the severity of cervical lesions; however, it is not related to HPV infection. Both markers are not related to prognostic variables of patients with cervical carcinoma.
Ban Qasim; Husam Ali; Alaa Hussein
Volume 7, Issue 4 , September 2012, , Pages 215-223
Abstract
Background & Objective: The current approaches to reduce the risk of colorectal carcinoma are through the detection and removal of the precursor lesion” adenomatous polyps”. The study was conducted to evaluate the immunohistochemical expression of p53 and bcl2 in colorectal adenomas and ...
Read More
Background & Objective: The current approaches to reduce the risk of colorectal carcinoma are through the detection and removal of the precursor lesion” adenomatous polyps”. The study was conducted to evaluate the immunohistochemical expression of p53 and bcl2 in colorectal adenomas and carcinomas.
Patients and Methods: A total of 86 cases, 33 colorectal adenomas, 33 colorectal adenocarcinomas and 20 samples of non -tumerous colonic tissue as control, were included in this retrospective study. Sections were stained immunohistochemically for p53 and bcl2. Scoring was performed using Digimizer software. Data were analyzed using SPSS program (Statistical Package for Social Sciences) version 16 and Microsoft Office Excel 2007.
Results: The frequency of p53 positive cases was significantly higher in carcinoma than adenoma while the frequency of bcl2 positive cases was significantly higher in adenoma than carcinoma. P53 expression was significantly higher in large sized adenomas, villous configuration, severe dysplasia, and multiple lesions. Bcl2 expression showed significantly correlated with adenomas of small size, solitary, tubular, and mild dysplasia. There was a significant correlation between bcl2 expression and non-mucinous carcinoma and a negative correlation with tumor size.Therewas an inverse relationship between bcl2 and p53 expression in both colorectal adenomas and carcinomas.